Callie Coombs, Associate clinical professor at University of California, Irvine, posted on X:
“CLL13 longer follow up – huge study and great presentation. Though GIV is superior, I would not use as SOC since the duration of therapy is longer (range 12-36 months) than ven/obi which is still quite excellent (and always 1 yr). And yes MRD still matters!”
More posts featuring EHA 2025.